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Abstract
Background: Chronic Lymphocytic Leukemia (CLL) pathogenesis has been linked to the prolonged survival and/or
apoptotic resistance of leukemic B cells in vivo, and is thought to be due to enhanced survival signaling responses to
environmental factors that protect CLL cells from spontaneous and chemotherapy-induced death. Although normally
associated with cell migration, the chemokine, CXCL12, is one of the factors known to support the survival of CLL cells. Thus,
the signaling pathways activated by CXCL12 and its receptor, CXCR4, were investigated as components of these pathways
and may represent targets that if inhibited, could render resistant CLL cells more susceptible to chemotherapy.
Methodology/Principal Findings: To determine the downstream signaling targets that contribute to the survival effects of
CXCL12 in CLL, we took a phosphoproteomics approach to identify and compare phosphopeptides in unstimulated and
CXCL12-stimulated primary CLL cells. While some of the survival pathways activated by CXCL12 in CLL are known, including
Akt and ERK1/2, this approach enabled the identification of additional signaling targets and novel phosphoproteins that
could have implications in CLL disease and therapy. In addition to the phosphoproteomics results, we provide evidence
from western blot validation that the tumor suppressor, programmed cell death factor 4 (PDCD4), is a previously
unidentified phosphorylation target of CXCL12 signaling in all CLL cells probed. Additionally, heat shock protein 27 (HSP27),
which mediates anti-apoptotic signaling and has previously been linked to chemotherapeutic resistance, was detected in a
subset (,25%) of CLL patients cells examined.
Conclusions/Significance: Since PDCD4 and HSP27 have previously been associated with cancer and regulation of cell
growth and apoptosis, these proteins may have novel implications in CLL cell survival and represent potential therapeutic
targets. PDCD4 also represents a previously unknown signaling target of chemokine receptors; therefore, these
observations increase our understanding of alternative pathways to migration that may be activated or inhibited by
chemokines in the context of cancer cell survival.
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Introduction
B cell Chronic Lymphocytic Leukemia (CLL) is an adult
leukemia characterized by the accumulation of B cells in the
blood, bone marrow and secondary lymphoid tissues due to
apparent survival advantages and/or apoptosis resistance of these
cells in vivo [1]. There is significant heterogeneity in the disease
progression between CLL patients. A more aggressive form of the
disease, which results in lower patient survival time, correlates with
markers including unmutated immunoglobulin heavy chain
variable region (IgHV) status and high expression of the tyrosine
kinase ZAP-70 (ZAP-70+). Although the accumulation of a
monoclonal population of CD5+/CD19+ B cells is characteristic
of both prognostic groups, aggressive CLL appears to have some
distinct characteristics and signaling properties compared to
indolent CLL [2].
Despite their enhanced survival in vivo, when CLL cells from
patients are cultured in vitro, they rapidly undergo apoptosis under
conditions that support the survival of normal B cells, underscor-
ing the dependence of these cells on survival cues from the
microenvironment [3,4]. In the microenvironment, marrow
stromal cells are believed to secrete factors that promote CLL
cell survival in patients; correspondingly, when monocytes isolated
from peripheral blood of CLL patients are cultured, they
differentiate into ‘‘Nurse-like cells’’ (NLCs) that promote CLL
survival in vitro [3]. One of the factors known to be secreted by
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CXCL12 (SDF-1). Additionally, CXCR4, the receptor for
CXCL12, is overexpressed on CLL cells compared to normal B
cells, and thus has the potential for enhanced responsiveness to
CXCL12 signaling [5]. Although another chemokine receptor,
CXCR7, can also bind CXCL12 and was previously shown to be
expressed on B cells [6], surface expression of CXCR7 was not
observed on CLL B cells (Figure 1). Therefore the CXCL12
signaling effects are likely mediated exclusively by CXCR4 in
these cells.
While chemokines and their G-protein coupled receptors are
best known for their role in directing the migration of immune
cells, it is clear that these proteins are involved in many other
biological functions. The CXCL12/CXCR4 axis is critical for
developmental processes including lymphopoiesis, and central
nervous system and cardiac development, and knockout of either
the ligand or receptor in mice results in embryonic lethality [7].
Due to the involvement of CXCL12/CXCR4 in migration,
angiogenesis, and development, it is not surprising that this axis is
often exploited by cancer cells for metastasis as well as survival and
proliferation [8]. However, the specific molecular mechanisms by
which these various functions are effectuated and how these
signaling pathways target different downstream signaling mole-
cules in cancer cells compared to non-malignant counterpart cells
is largely unknown. Similarly, while it is known that Akt and
ERK1/2 are activated by CXCL12 in CLL, the downstream
targets of these pathways and activation of other pathways have
not been elucidated [9].
Despite the upregulation of CXCR4 and strong Akt and ERK
signaling demonstrated by CLL cells in response to CXCL12, the
CLL cells actually migrate less efficiently to CXCL12 than B cells
from healthy donors in a transwell migration assay (Figure 2).
Thus, in CLL cells, it appears that signaling downstream of
CXCL12/CXCR4 may be redirected towards survival signaling
in lieu of cell migration. To better characterize the signaling
responses to CXCL12 stimulation, primary CLL cells isolated
from 5 patients were subjected to phosphoproteomic analysis by
liquid chromatography and tandem mass spectrometry (LC-MS/
MS). Rather than attempting to characterize the complete
phosphoproteome of CLL cells, this approach was designed to
generate new hypotheses about the CXCL12/CXCR4 signaling
network in CLL survival, and to identify downstream proteins that
might be good therapeutic targets. While many phosphoproteins
were identified in the CLL cells, comparison of spectral counts
between CXCL12 stimulated and unstimulated cells allowed
identification of proteins phosphorylated as a consequence of
CXCL12/CXCR4 signaling. With follow-up experiments, the
Figure 1. CXCR7 Expression on Normal B cells and CLL B Cells.
Surface CXCR7 expression on Normal B cells (solid line) and CLL B cells
(dashed line) was analyzed by flow cytometry and referenced to an
IgG1 isotype control (filled histogram). Profiles are representative of B
cells from 4 healthy donors (normal B cells) and 10 CLL patients’ B cells.
doi:10.1371/journal.pone.0011716.g001
Figure 2. CXCL12-mediated Migration of CLL B Cells and
Normal B Cells. A) Representative migration assay profiles for normal
B cells (solid line) compared to 2 different CLL patients’ cells (dashed
lines) performed in triplicate over a range of 0–100 nM CXCL12 and
normalized to no chemokine. Data represents the percent of cells
migrated through the transwell filter. B) Bar graph comparing the
maximum percent cell migration observed in normal B cells and CLL B
cells. Data represents an average of multiple transwell migration assays
from separate donors, normal B cells n=5, CLL B cells n=7, each
performed in triplicate. Differences were found to be statistically
significant (p,0.0001) based on Student’s t-test. C) Table depicting the
maximum percent migration to CXCL12 (efficacy) and the concentration
at which maximal migration is achieved (potency) observed in normal B
cells compared to CLL B cells.
doi:10.1371/journal.pone.0011716.g002
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phosphorylation target of CXCL12 signaling in all CLL patient
cells examined (n=10) and HSP27 was similarly validated in a
subset of CLL patients (,25%). Although these proteins have been
previously linked to cancer cell survival, they have not been
previously associated with CLL nor has PDCD4 been established
as a downstream phosphorylation target of CXCL12 signaling.
Furthermore, a number of other proteins (many of which do not
have commercially available phospho-specific antibodies available)
have been proposed as potential downstream phosphorylation
targets of CXCL12 stimulation based on spectral count analysis of
the CLL phosphoproteomics data.
Methods
Cells and reagents
Peripheral blood mononuclear cells (PBMCs) were obtained
from leukopheresis samples of CLL patients following written
consent at the Rebecca and John Moores Cancer Center at the
University of California San Diego (UCSD), in compliance with
the Declaration of Helsinki. These studies were approved by the
Institutional Review Board of UCSD. PBMCs were isolated by
Ficoll-Paque (GE Healthcare) density gradient centrifugation as
previously described [9]. The isolated PBMCs were used fresh and
cultured for phosphoproteomics analysis or frozen as liquid
nitrogen stocks in 90% heat inactivated fetal bovine serum
(FBS)/10% DMSO for follow-up analysis by western blot. PBMCs
used in the proteomics experiments were determined to be .90%
CLL B cells as assessed by CD5+/CD19+ staining and flow
cytometry analysis. For western blot validation, CLL B cells were
purified from the PBMCs by negative selection using the magnetic
associated cell sorting (MACS) (Miltenyi Biotec, Auburn, CA) by
depletion of CD14+ (monocytes) and CD2+ (T cells) cells, leading
to .99% CLL B cell purity. Normal B cells were purified from
PBMCs from healthy donors (San Diego Blood Bank) using the
MACS B cell Isolation Kit II (Miltenyi Biotec, Auburn, CA)
according to the manufacturer’s protocol and were determined to
be .90% pure by flow analysis staining for CD19+/CD3-/CD14-
cells. RPMI-1640 glutamax media and FBS were obtained from
Gibco (Invitrogen, Carlsbad, CA).
Recombinant CXCL12 preparation
CXCL12 was expressed recombinantly in BL21 E. coli as
previously described [10]. In brief, CXCL12 was expressed as a
His-tag fusion protein and purified from inclusion bodies. Bacterial
cell pellets were sonicated and washed with deoxycholate following
resuspension in 10 mM Tris pH 8.0 with 1 mM MgCl2, 200 mg
DNAse, and Complete Protease Inhibitor Cocktail (EDTA-free)
(Roche, Indianapolis, IN). Protein was then solubilized in 6 M
Guanadine-HCl, 100 mM sodium phosphate, 10 mM Tris-Cl,
pH 8.0, using a dounce homogenizer. CXCL12 was purified over
a Ni-NTA column and refolded with Hampton Fold-It Buffer #8
(Hampton Research, Aliso Viejo, CA), then dialyzed and
concentrated using Amicon Ultra centrifugal concentrators
(MWCO=5000). The His-tag was removed by cleaving with
enterokinase (NEB, Ipswich, MA) at a 1:100,000 molar ratio
overnight at room temperature. CXCL12 was then purified by
HPLC and the identity and purity was validated by ESI mass
spectrometry. Transwell migration assays on Jurkat cells were used
to validate functionality of the purified CXCL12.
Migration assays
Transwell migration assays (Corning, Corning, NY) were
performed on purified CLL B cells and B cells from healthy
donors using inserts with a 6.5 mm diameter, 5.0 mm pore size.
Cells were resuspended at 2.5610
6 cells/mL in RPMI+10%FBS
and 100 mL of cell suspension was added to the inserts. CXCL12
was diluted over a concentration range of 0 nM to 500 nM in a
600 mL total volume of RPMI+10%FBS in the bottom wells. As a
positive control and cell count reference, cells were added directly
to the wells without inserts. Transwell migration was conducted for
2 h at 37uC/5%CO2. Cells that had migrated into the bottom
wells were then collected and counted by flow cytometry on a
FACSCalibur (BD Biosciences, San Jose, CA). Data was
normalized to no chemokine control and percent migration was
calculated from the positive reference control.
Preparation of CLL lysates for proteomics
CLL cell lysates for phosphoproteomic analysis were prepared
as previously described [10]. Briefly, 3610
9 total CLL PBMCs
were washed with sterile PBS and resuspended at 1610
7 cells/mL
in serum-free RPMI-1640 media. The CLL cell suspension was
distributed evenly into five 15 cm plates (6610
8 cells/plate)
(Corning Inc, Corning, NY) and cultured for 2 h at 37uC/5%
CO2 prior to stimulation with CXCL12. CLL cells were then
either unstimulated or stimulated for 3 min, 10 min, 30 min, or
60 min with 30 nM CXCL12. All plates were harvested at the
same time with 3 mL ice cold cytoplasmic lysis buffer containing
10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM
dithiothreitol (DTT) (Sigma, St. Louis, MO), Complete Protease
Inhibitor Cocktail (Roche Diagnostics, Indianapolis, IN), and Halt
Phosphatase Inhibitor Cocktail (Pierce, Rockford, IL) for 30 min
on ice. Lysates were clarified by centrifugation at 20,000 rcf for
20 min at 4uC. The supernatants were distributed into protein
LoBind Eppendorf tubes (Eppendorf, Westbury, NY) and stored at
–80uC. The total protein concentration of the CLL lysates was
determined using a BCA protein assay (Pierce, Rockford, IL).
IMAC phosphopeptide enrichment
IMAC enrichment was performed as previously described [10].
Briefly, 2 mg of CLL lysates were denatured with 1% sodium
dodecyl sulfate (SDS) (Fisher Scientific, Pittsburgh, PA), reduced
with 10 mM DTT, and alkylated with iodoacetamide (Sigma, St.
Louis, MO). Proteins were then precipitated with 50% ethanol/
50% acetone/0.1% acetic acid (HAC). The pellets were
resuspended in 6 M urea/0.1 M Tris, pH 8.0, and vortexed to
solubilize the protein. The urea concentration was then diluted
five-fold by addition of 50 mM Tris, pH 8.0 and protein was
digested overnight at 37uC using sequencing-grade modified
trypsin (Promega, Madison, WI) at a ratio of 1:50 (trypsin:protein).
Trypsin was inactivated by acidification of the digests with
trifluoroacetic acid to 0.3 to 0.5% (v/v). Prior to IMAC
enrichment, peptide mixtures were desalted with 50 mg Sep-pak
C18 cartridges (Waters Corp, Milford, MA). IMAC beads were
prepared by stripping Ni-NTA spin column resin (Qiagen,
Valencia, CA) and recharging the beads with 100 mM FeCl3
(Fluka reagent, Sigma, St. Louis, MO). IMAC beads were then
packed into gel loading tips with glass wool and conditioned with
25% Acetonitrile (ACN)/0.1% HAC. Nonspecific peptides were
removed by washing twice with 30 mL of 25% ACN/0.1% HAC/
0.1 M NaCl, twice with 0.1% HAC, and twice with 30 mLo f
Milli-Q H2O. Phosphopeptides were eluted with a total volume of
50 mL over three elutions with 1% phosphoric acid. All fractions
were collected in protein LoBind Eppendorf tubes, speed-vac
dried, and stored at –20uC until MS analysis. Analysis of IMAC
washes and flow through by LC-MS/MS confirmed successful
binding of phosphopeptides to the IMAC columns as less than
0.1% of these peptides were found to be phosphorylated, and the
CXCL12 Signaling in CLL
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identified in the IMAC enriched samples.
Mass spectrometry and data processing
IMAC-enriched CLL peptides were resuspended in Milli-Q
H2O +0.1%HAC and analyzed by reversed-phase, C18 capillary
liquid chromatography and tandem mass spectrometry (LC-MS/
MS) on a Thermo-Finnigan LTQ ion trap mass spectrometer. The
capillary LC columns (,17 cm) were pulled and packed in-house
using deactivated fused silica (100 mm) (Agilent, Santa Clara, CA)
as previously described [10]. Angiotensin II (Sigma-Aldrich, St.
Louis, MO) was run after every two CLL sample runs as a control
for column performance. The standard method used for all
samples was as follows: 95% A/5% B (buffer A=0.1% HAC in
HPLC-grade Milli-Q H2O, buffer B=0.1% HAC in HPLC-grade
ACN) for 20 min, 60% A/40% B for 30 min, 20% A/80% B for
6 min, followed by a final washing step of 95% A/5% B for
30 min at 250 ml/min. A flow rate of 200 to 500 nL/min through
the capillary column was achieved by splitting the flow of solvent
before it reached the column. Samples were run in data-dependent
mode in which the spectrometer performed one full MS scan
followed by six MS/MS scans of the top six most intense ions in
the parent spectrum with an m/z ranging from 400 to 2000. The
dynamic exclusion list was varied in order to get a range of
coverage and spectral counts. The standard dynamic exclusion list
applied had a repeat count of 1, a repeat duration of 30 s, an
exclusion size of 100, an exclusion duration of 180 s, and an
exclusion mass width of 1.50. Other variations included a list of
the top 25 peptides with a repeat duration of 60 s, an exclusion of
the top 5 most abundant peptides, and a dynamic exclusion list
turned off. The spray voltage was 1.8 kV. On average, the scan
rate in this experiment ranged from four to eight scans per second.
A comprehensive phosphoproteomics data set from cells of one
particular patient (CLL A) with unmutated IgHV and ZAP-70+
status (indicative of more aggressive disease) was collected from
two separate triplicate runs and one duplicate run in order to
obtain good coverage and number of spectra for comparison.
Phosphoproteomics analyses of 4 additional CLL patients’ cells
(CLL B – E) (each run in single triplicate experiments) were also
performed to ensure reproducibility between different patient cells
and stimulations. CLL B, D and E also had more aggressive (high
ZAP-70) characteristics (high ZAP-70) while CLL C was of the
indolent (low ZAP-70) subgroup. Following data collection, RAW
data files were converted to mzXML data files using the program
ReAdW (http://tools.proteomecenter.org/ReAdW.php). Data
analysis of the MS/MS spectra was performed using the open-
access database search tool, InsPecT [11,12], with the UniProt
human database, the UniProt shuffled human decoy database as
well as common contaminants databases (e.g. keratin). Peptide
sequencing searches were defined for tryptic cleavage restraints
and to allow for modification of up to two phosphorylation sites
(Ser, Thr, or Tyr) on a peptide. Spectra were sorted by p-values
according to the InsPecT scoring function and the target decoy
database was used as a measure of the overall quality of MS/MS
data. Peptides smaller than 7 amino acids and peptides with more
than one missed cleavage were excluded from analysis. Peptides
with a false discovery rate (FDR) of less than 1–2% were manually
validated for positive identification.
Western blots and antibody reagents
For western blot analysis, patient CLL cells used for phosphopro-
teomics as well as additional patient’s cells were used. Purified CLL B
cells were cultured in serum-free RPMI at 1610
7 cells/mL for 2 h at
37uC/5%CO2 and then stimulated with 30 nM CXCL12 over an
hour time course (unstimulated, 3, 10, 30 and 60 min) or for 4 h,
10 h, and 24 h for PDCD4 degradation analysis. For inhibitor
studies, CLL cells were pre-treated with 40 mM AMD3100 (Sigma)
or 200 ng/ml Pertussis toxin (List Biological Laboratories) for 1 h
prior to stimulation with CXCL12. Coculture of CLL cells with
NLCs was performed as previously described [3,9] and then the CLL
cells were collected and centrifuged for harvest. Cells were lysed on
ice for 30 min in Ripa buffer (10 mM Tris pH 7.4, 150 mM NaCl,
1% Triton X, 0.1% Na-Deoxycholate, 0.1%SDS and 5 mM EDTA)
containing Complete Protease Inhibitor Cocktail (Roche, Palo Alto,
CA) and Halt Phosphatase Inhibitors (Pierce). Lysates were clarified
by centrifugation at 20,000 rcf for 10 min at 4uC. A BCA protein
assay (Pierce) was performed to determine total protein concentration
and 20 mg of total protein was loaded into each well of a Criterion 4–
12% Bis-Tris gel and run with the XT MES buffer system (Bio-Rad,
Hercules, CA). Gels were transferred onto PVDF membranes (Bio-
Rad), blocked with 5% milk-TBST, and incubated overnight at 4uC
with primary antibodies. Blots were washed 3 times for 10 min with
Tris Buffered Saline +0.1% Tween (TBST) and then incubated for
1 h at room temperature with secondary antibodies conjugated to
HRP, washed again 3 times with TBST and then developed with
Figure 3. Flow Chart of CLL Phosphoproteomics Analysis. Lysates
were prepared from primary CLL B cells that had been stimulated over an
hour time course with 30 nM CXCL12. Lysates were denatured, reduced
and alkylated in preparation for trypsin digest. Tryptic peptides were then
enriched for phosphopeptides by IMAC and LC-MS/MS was performed.
Data was analyzed using the InsPecT database search algorithm for
phosphorylations on Ser, Thr, or Tyr. A decoy database and manual
validation of the spectra were used as quality control. Spectral count
comparisonsweremadeasaqualitativeassessmentofCXCL12stimulation
response and interesting target proteins were selected for follow-up
studies if antibodies were available.
doi:10.1371/journal.pone.0011716.g003
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sensitivity reagent (Pierce). Blots were stripped with Restore western
blot stripping solution (Pierce) for 10 min at room temperature and
then re-probed with other antibodies and/or b-actin as a loading
control. Primary antibodies were diluted into 5% BSA-TBST at
recommended concentrations. Phospho-PDCD4 and PDCD4 anti-
bodies were obtained from Rockland Immunochemicals. Phospho-
p38, phospho-HSP27, HSP27, phospho-S6K, and b-actin were
obtained from Cell Signaling Technology. Densitometry analysis was
performed using ImageJ software (NIH) and normalized to b-actin
loading controls.
Flow cytometry
CLL B cells or normal B cells were purified for flow cytometry
analysis. Cells were washed and resuspended in a 0.5% bovine serum
albumin (BSA) (Sigma) in Phosphate Buffered Saline (PBS) solution
and stained for CXCR7 expression using an APC-conjugated
antibody (clone 11G8) (R&D systems) or an APC-conjugated IgG1
isotype control according to manufacturer’s protocol (R&D systems).
Flow cytometry data was collected on a FACSCalibur cytometer (BD
Biosciences) and analyzed using FlowJo software.
Results
Normal B cells migrate with higher efficacy and potency
to CXCL12 than CLL B cells, despite having lower levels of
CXCR4
Chemokines, including CXCL12, are best known for their role
in directing cell migration, but it is well established that they can
also induce cell survival and proliferation [8]. This observation can
be rationalized by the fact that some of the major pathways
involved in cell migration (e.g. PI3K/Akt and Raf/MEK/ERK),
are also important for survival and proliferation signaling [13].
However, little is known regarding the extent to which there is
Figure 4. Overlap in Phosphoprotein Identification between CLL cells from Different Patients. A) Venn diagram illustrating the degree of
overlap between the phosphoproteins identified in CLL A compared to the phosphoproteins identified in CLL B, C and D. B) Matrix table outlining the
number of overlapping phosphoproteins identified for CLL A, B, C and D.
doi:10.1371/journal.pone.0011716.g004
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these pathways in the context of migration versus survival/
proliferation. Since it has been established that CLL cells have up-
regulated expression of CXCR4 compared to normal B cells, and
that CXCL12 stimulation of CLL cells activates Akt and ERK1/2
pathways, transwell migration assays were performed on purified
CLL B cells and normal B cells to compare their ability to migrate
towards CXCL12 [5,8,9].
Surprisingly, the normal B cells showed a significantly greater
(p,0.0001) ability to migrate to CXCL12, with respect to both
efficacy (4.5+/21.2% migration in normal vs. 0.85+/20.48%
migration in CLL cells) and potency (,10 nM in normal vs
,50 nM in CLL cells) (Figure 2). Although it was expected that
the CLL cells would have the stronger migratory response due to
higher CXCR4 expression, these results are consistent with
previously published observations that showed weak migration of
CLL cells to CXCL12 compared to a much more robust response
to the CCR7 ligands, CCL19 and CCL21 [14,15]. These data
suggest that the downstream effects of CXCR4 may be redirected
for survival rather than migration, and led us to consider what
other pathways or downstream targets of Akt or ERK1/2 might
be activated to bias the CXCL12 signaling response towards
survival. Taking a global approach to this question, we performed
mass spectrometry-based phosphoproteomics analysis of unstimu-
lated and CXCL12-stimulated CLL cells.
Characterization of phosphopeptides/phosphoproteins
in CXCL12-stimulated CLL cells via mass spectrometry
Fresh PBMCs from 5 CLL patients were stimulated over an
hour time course with CXCL12, and lysates were generated for
IMAC enrichment and LC-MS/MS analysis. Multiple (3 separate
duplicate or triplicate experiments with variable acquisition
methods) phosphoproteomics data sets were acquired on lysates
from the cells of a patient with ZAP-70+ aggressive CLL, referred
to as ‘‘CLL A’’, in order to ensure good coverage of the proteomic
space. Smaller phosphoproteomics data sets (single triplicate
experiments) were collected from cells of 4 additional patients
(CLL B to E) for comparison.
Protein lysates from the CLL cells were trypsin digested and
enriched for phosphopeptides via immobilized metal affinity
chromatography (IMAC) to yield a highly enriched population
of phosphorylated peptides. Phosphopeptides were analyzed by
LC-MS/MS using a linear iontrap (LTQ) mass spectrometer.
Data was processed using the InsPecT database search algorithm
and the spectra were manually inspected for validation (see flow
diagram Figure 3).
Over 10,000 spectra were collected from the combined
phosphoproteomics analysis of unstimulated as well as stimulated
CLL cells, which was comprised of 1470 phosphopeptides
(.1200 unique phosphosites) from 696 phosphoproteins (Table
S1). In general, a .30% enrichment of annotated phosphopep-
tides was achieved from our IMAC procedure, which is on par
with other phosphopeptide enrichment studies of mammalian
cells [16].
To ensure that good coverage of the CLL A data set was
obtained, a comparison was made of the overlapping phospho-
proteins identified in the CLL A data sets and the smaller CLL
B - E data sets. 538 of the 696 total phosphoproteins (.77%)
identified in the CLL A data sets were also identified in data sets
B - E, suggesting detection of the majority of phosphopeptides
detectable by these methods. Also, many of the non-overlapping
phosphoproteins identified in CLL B to E but not in CLL A
were isoform variants of phosphoproteins detected in CLL A.
Figure 4 depicts the overlap of CLL B - E with CLL A
(Figure 4A) and the matrix shows overlap between all of the
CLL samples (Figure 4B).
Identification of phosphoproteins with prior correlations
to CLL and other leukemias
Adding confidence to our phosphoproteomics results, a number
of hematopoietic-specific phosphoproteins as well as phosphopro-
teins with prior implications in CLL and other leukemias were
identified. Table 1 highlights 9 of the phosphoproteins detected
with previous links to CLL/leukemia, including Hematopoietic
cell-specific Lyn substrate (Hcls1) and SH2-containing inositol
phosphatase-1 (SHIP-1). The phosphorylation status of both Hcls1
Table 1. Phosphoproteins identified by LC-MS/MS analysis with prior implications in CLL/leukemia disease.
Protein Gi Accession Implications in CLL/leukemia References
B cell novel protein 1 (BCNP1) 31542207 Overexpressed in CLL and other B cell malignancies compared to
normal B cells
Boyd et al 2003
Formin-like 1 (FMNL1) 33356148 Akt interacting partner found to be overexpressed in CLL Favaro et al 2003
Hematopoietic cell-specific Lyn
substrate (Hcls1 or HS1)
4885405 Phosphorylation correlated with shorter mean patient survival time in CLL Scielzo et al 2005
HSP-90 alpha 92859630 Stabilizes Akt and ZAP-70 signaling in CLL, highly activated in CLL,
and role in CLL survival
Castro et al 2005
Lyn (Yamaguchi sarcoma viral
(v-yes-1))
4505055 Overexpressed in CLL compared to normal B cells, potential anti-apoptotic
function in CLL
Contri et al 2005
Minichromosome maintenance
protein 2 (Mcm2)
33356547 Role in DNA replication, marker for proliferation and prognosis in B-cell
lymphoma
Obermann et al 2005
promyelocytic leukemia protein
(PLZF)
4505903 Correlates with apoptotic resistance, higher expression of PLZF
associated with lower CLL patient survival
Parrado et al 2000
SH2 containing inositol
phosphatase 1 (SHIP-1)
64085167 Phosphorylation status segregated with ZAP-70, correlated with
aggressive disease in CLL
Gabelloni et al 2008
Stathmin 1 (oncoprotein 18) 44890052 Overexpressed in acute leukemia cells compared to normal
lymphocytes, involved in cell growth and proliferation
Melhem et al 1991
Table listing select proteins identified by LC-MS/MS with prior implications in CLL or other related leukemias along with the GI accession number, a brief description of
biological implications, and references [17,19–20,22,41–45].
doi:10.1371/journal.pone.0011716.t001
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aggressiveness and shorter mean survival [17,18,19], consistent
with the aggressive characteristics of CLL A.
Also included in Table 1 are phosphoproteins which have been
linked to CLL but not necessarily phosphorylation status,
including HSP90, B cell novel protein 1, promyelocitic leukemia
protein, and formin-like 1 (FMNL1) [20,21,22]. These proteins
have general implications in CLL, but whether differences in
phosphorylation status affect the activity or function in disease is
unclear. A few additional proteins including minichromosome
maintenance protein 2 and stathmin 1 have been linked to disease
progression of other leukemias, but not directly to CLL and thus
warrant further investigation in CLL. Many of these phosphopro-
teins did not appear to exhibit changes in phosphorylation in
response to CXCL12 or spectral numbers were too low to make an
assessment of stimulation response, but HSP-90 and Mcm2 could
be potential phosphorylation targets and are thus also highlighted
as proteins of interest in Table 2.
Identification of novel downstream targets of CXCL12/
CXCR4 signaling in CLL
To semi-quantitatively assess whether phosphorylation of some of
the proteins is a consequence of CXCL12 stimulation, spectral counts
from the mass spectrometry runs on the stimulated samples off CLL
A were compared to those from unstimulated samples. Select
candidate targets of CXCL12-induced phosphorylation are reported
in Table 2 along with their associated spectral counts. A number of
known targets of survival signaling pathways including programmed
cell death factor 4 (PDCD4) and heat shock protein 27 (HSP27) were
identified as having more spectral counts in the stimulated versus
unstimulated samples, and were selected for validation by western
blot and further analysis, discussed in detail later. Validation was
performed on lysates from CLL cells used in phosphoproteomics
analysis (lettered CLL A to E) as well as additional patient cells not
examined by phosphoproteomics (CLL1, CLL2, etc) in order to
determine consistency of these responses across different patients,
since CLL is a heterogeneous disease [1].
Table 2. Select phosphoproteins from phosphoproteomics analysis with spectral count numbers and known functions.
Adenylyl cyclase-associated
protein (CAP1)
5453595 5; 8; 14; 17; 12 Invovled in cAMP pathway, overexpressed in
pancreatic cancer, correlated with poor prognosis
Yamazaki et al 2009
Heat shock protein 27 kDa
(HSP27)
7706687 1; 10; 13; 7; 7 Downstream target of p38-MAPKAPK2 pathway;
involvement in IkB degradation, protection from
apoptosis, sequestering and inhibiting cytochrome c
release, interacts with Akt
Parcellier et al 2003;
Garrido et al 2006
Heterogeneous nuclear
ribonuclear proteins (U, D, A1)
U (14141161), D
(14110414), A1
(45044445)
U (0; 14; 11; 6; 7),
D (3; 21; 25; 20; 14),
A1 (13; 33;16; 40; 17)
Nucleocytoplamic shuttling proteins that shuttle
mRNAs from site of transcription to start of translation;
hnRNPA1 levels are increased in chronic myelogenous
leukemia (CML), implications in apoptotic resistance
and tumorigenesis; potentially regulated by
phosphorylation by various MAPKs
Lervolino et al 2002;
Eiring et al 2008; Van der
Houven van Oordt et al
2000
HSP90-alpha 92859630 2; 24; 18; 21; 12 Stabilizes PI3K and Akt, pro-proliferative and
tumorigenic effects, important for Jak-STAT
signaling, Implicated with ZAP-70 stability and
signaling in aggressive CLL, less known regarding
phosphorylation
Castro et al 2005; Fujita
et al 2002; Sato et al
2000; Schoof et al 2009
L-Plastin (lymphocyte
cytosolic protein 1)
4504965 0; 4; 9; 1; 1 Actin binding protein expressed in hematopoietic
lineage cells as well as malignant cells of non-
hematopoietic origin; important for cell polarization
and motility
Lin et al 1993; Morley et
al 2010
Lymphocyte specific
protein 1 (LSP1) (S252)
61742789 1; 9; 11; 5; 8 Downstream target of p38-MAPKAPK2 pathway,
PKC, GSK3; F-actin binding protein involved in
chemotaxis
Wu et al 2007
Minichromosome maintenance
protein 2 (Mcm2)
33356547 2; 7; 2; 4; 2 Role in DNA replication, marker for
proliferation and prognosis in B-cell lymphoma
Obermann et al 2005
Programmed cell death factor 4
(PDCD4)
21735596 5; 11; 10; 9; 14 Inhibition of AP1 transcription and eiF4A
translational activity, phosphorylation by Akt
and p70 S6K is inhibitory and promotes its
degradation
Yang et al 2001; Yang et
al 2003; Palamarchuk et
al 2005; Lankat-
Buttgereit et al 2009
serine/arginine repetitive matrix 1
(SRm160)
42542379 15; 57; 57; 40; 30 RNA splicing coactivator; regulates CD44
alternative splicing with potential role
in tumor cell invasion
Cheng and Sharp 2006
Small acidic protein 7657234 1; 18; 10; 14; 6 Very little information available, unknown function
Splicing factor 1 (SF) 42544125 0; 14; 13; 21; 13 Regulates premesseger RNA splicing and
gene transactivation and including that of
b-catenin/TCF4 complex. Phosphorylated
by protein kinase KIS enhances binding to U2AF65
Shitashige et al 2007;
Manceau et al 2006
UV excision repair protein RAD23
homolog A (RAD23A, hHR23)
4826964 0; 19; 10; 12; 3 Involved in nucleotide excision repair,
recognition of DNA damage; implicated in p53
degradation; phosphorylation function unknown
Glockzin et al 2003
Spectral count numbers for select phosphoproteins of interest are presented for each CXCL12 (30 nM) stimulation time point (0; 3; 10; 30; 60 min). A brief description of
known functions and corresponding references are also provided [21–24,26,28–29,43,46–60].
doi:10.1371/journal.pone.0011716.t002
CXCL12 Signaling in CLL
PLoS ONE | www.plosone.org 7 July 2010 | Volume 5 | Issue 7 | e11716Figure 5. CXCL12 Induces Phosphorylation of PDCD4 at Ser457. A) Bar graph depicting the spectral counts of PDCD4 phosphopeptides
observed in the LC-MS/MS analysis at time points of CXCL12 stimulation. B) Western blot of PDCD4 phosphorylation over time course of 0 to 60 min
CXCL12 stimulation (30 nM) from CLL A patient cells. b-actin served as a loading control. C) Top panel: Representative western blot of PDCD4
phosphorylation in CLL cells from 2 different CLL patients not used in LC-MS/MS analysis over 30 nM CXCL12 stimulation time course. b-actin served
CXCL12 Signaling in CLL
PLoS ONE | www.plosone.org 8 July 2010 | Volume 5 | Issue 7 | e11716Some of the phosphoproteins identified in this study have been
previously implicated in cancer malignancy such as Mcm2 and
adenylyl cyclase associated protein (CAP1), while little informa-
tion is available on some of the other potential targets including
small acidic protein (Table 2). Although two of the proteins
(PDCD4 and HSP27) are validated herein as targets of CXCL12-
signaling in CLL, the remaining phosphoproteins, while beyond
the scope of this work, pose interesting targets for future
investigations.
CXCL12 induces the phosphorylation and degradation of
PDCD4
PDCD4 is one of the phosphoproteins that appeared to be
induced by CXCL12 stimulation based on spectral counts
(Figure 5A and Table 2). It is a known tumor suppressor, and
downstream phosphorylation target of Akt, which is known to be
activated by CXCL12 in CLL cells [9]. A phospho-specific
antibody is also commercially available, making it attractive for
follow-up studies [23,24]. As a tumor suppressor protein, PDCD4
has been implicated in a number of cancers where it is often
inhibited and/or downregulated, disrupting its ability to inhibit
eIF4A translational and AP-1 transcriptional activity, processes
that are important for cell growth and survival (Figure 5G).
Phosphorylation of PDCD4 is known to occur by Akt and p70
S6Kinase (p70S6K) which inhibits its activity and leads to its
ubiquitination and proteosomal degradation [23,24,25,26].
Three separate phosphopeptides from PDCD4 were detected from
our analysis: R.FVSpEGDGGR.V (Ser457), R.SGLTVPTSpPK.G
(Ser94) and R.DSGRGDSpVSDSGSDALR.S (Ser76) (Figure S1).
The R.FVSpEGDGGR.V phosphopeptide corresponds to Ser457
phosphorylation, a site known to be phosphorylated by Akt [23].
Therefore, multiple CLL patient samples were examined for PDCD4
phosphorylationin responseto CXCL12by westernblot. An increase
in phosphorylation of PDCD4 at Ser457 was observed upon
CXCL12 stimulation in CLL A cells (Figure 5B), as well as all 9
additional CLL patient cells examined (representative western blot in
Figure 5C). Increases in PDCD4 phosphorylation levels was variable
between patients and ranged from 1.7-fold to 7.4-fold and averaged
to approximately 3.4-fold (n=10), as quantified by densitometry
analysis of western blots (Figure 5C). Although variability was noted,
this variation did not cluster according to disease aggressiveness.
As a control to ensure that the phosphorylation was dependent
on CXCL12/CXCR4 signaling and to determine if the effects
were dependent on signaling through the G-protein, Gi, CLL cells
were pretreated with the small molecule CXCR4 antagonist,
AMD3100, or the Gi-inhibitor, pertussis toxin (PTx) prior to a
3 min stimulation with CXCL12. As shown in Figure 5D, both
AMD3100 and PTx completely abrogated phosphorylation
suggesting it is CXCR4 and G-protein signaling dependent.
Furthermore, to ensure that phosphorylation of PDCD4 has
relevance in a more physiological context, the levels of PDCD4
phosphorylation were examined in CLL cells that had been
cultured with NLCs (+) compared to those without NLCs (2). As
with CXCL12 stimulation, the coculture of CLL cells with NLCs
led to an increase in the phosphorylated levels of PDCD4
(Figure 5D).
Since the phosphorylation of PDCD4 is known to lead to its
ubiquitination and degradation [23,25], we examined levels of
total PDCD4 over a 24 h time period (0, 4, 10 and 24 h) following
CXCL12 stimulation. As shown in Figure 5E, 24 h post-
stimulation resulted in PDCD4 degradation to ,45% of starting
levels.
Additionally, although it is well established that Akt is
phosphorylated downstream of CXCL12 signaling in CLL cells
[9], it has not been established whether p70S6K, another kinase
known to phosphorylate PDCD4 leading to its ubiquitination and
degradation, is activated in CLL cells by CXCL12. Western blot
analysis revealed that phosphorylation and thus activation of
p70S6K (Thr389) was induced by CXCL12-stimulation in the
CLL cells (Figure 5F).
HSP27 expression and phosphorylation is variable in CLL
cells
The other phosphoprotein investigated further was HSP27
(phosphopeptide: R.QLSphosSGVEIR.H, Ser82) (mass spectrum
shown in Figure S2). HSP27 was also selected due to spectral
counts indicative of phosphorylation upon CXCL12 activation of
CXCR4 (Figure 6A), its implications in cancer and protection
from apoptosis, and the availability of a phospho-specific antibody
at the Ser82 phosphorylation site [27,28,29]. Additionally, HSP27
is an interesting target since it is downstream of p38-MAPK
signaling [27] which has not received much attention in
association with CLL and therefore represents a pathway with
potentially novel implications in CLL survival.
Interestingly, while PDCD4 was found to be a common target
of CXCL12 signaling in all CLL samples examined, phospho-
HSP27 and total HSP27 protein were only detectable by western
blot in a subset of ,25% (3 out of 12) of CLL patients examined
(representative western blot Figure 6B). Nevertheless, HSP27 was
indeed present and did exhibit an increase in phosphorylation
upon CXCL12 stimulation in the CLL A patient samples from
which the phosphoproteomics data was collected (Figure 6B).
Since p38-MAPK is known to be upstream of HSP27 phosphor-
ylation, we also examined p38 phosphorylation among the CLL
patient samples (Figure 6C); correspondingly, we observed
detectable p38 phosphorylation only in the samples that also
exhibited the HSP27 phosphorylation (CLL A, Figure 6B).
Although no common factor could be determined among the
patients examined with detectable HSP27, a larger sample size
might identify common features of these cells and determine
whether HSP27 is influencing the survival of this subset of CLL
patients.
as a loading control. Bottom panel: Densitometry analysis of PDCD4 phosphorylation levels CXCL12 stimulation (30 nM) time points relative to
unstimulated controls and averaged from 10 separate CLL patient cells. Error bars represent standard error of the mean (SEM). D) Western blot of
PDCD4 phosphorylation in unstimulated/untreated CLL cells or 3 min CXCL12 stimulations (30 nM) in the presence (+) or absence (2)o f
preincubation (1 h) with AMD3100 (40 mM) or Pertussis toxin (PTx) (200 ng/ml). NLC lysate represents CLL cells cultured in presence of NLCs with no
further stimulation or treatment. CLL cells were removed from the adherent NLCs and lysed. b-actin served as a loading control. E) Top panel:
Representative western blot detecting total levels of PDCD4 in CLL cells following 0, 4, 10 or 24 h of 30 nM CXCL12 stimulation. b-actin served as a
loading control. Bottom panel: Bar graph quantifying total PDCD4 levels over 24 h time course of 30 nM CXCL12 stimulation compared to 0 h
unstimulated controls and normalized to b-actin levels by densitometry analysis of western blots. Data represented are mean +/2 SD of 3 separate
CLL patients’ cells. F) Western blot stripped and reprobed from Figure 4B for p70S6K phosphorylation (Thr389) over time course of 30 nM CXCL12
stimulation from CLL A patient cells (Top panel) and 2 other representative CLL patients’ cells (bottom panel). b-actin served as a loading control. G)
Diagram of PDCD4 signaling showing known upstream regulators as well as downstream targets. Akt and p70S6K are known to phosphorylate
PDCD4, thereby inhibiting its function in repressing eIF4A translational activity and AP-1 transcription.
doi:10.1371/journal.pone.0011716.g005
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CLL is the most common leukemia in the Western world [1]. The
accumulation of CLL B cells is believed to result from low rates of
precursor cell proliferation and via recruitment of accessory cells that
create a supportive microenvironment by producing factors that
foster CLL survival [1,2]. The chemokine, CXCL12, is one of the
cytokines produced by cells in the microenvironment that enhances
CLL survival in vitro and likely in vivo [9]. Although chemokines are
best known for their roleaschemoattractants, we show here that CLL
cells are much less capable of migrating to CXCL12 compared to
CLLBcells,despite anupregulationofCXCR4 onthe CLLcells[5].
While the low levels of migration may still play a role in vivo [30], it is
evident that the CXCL12/CXCR4 axis is also networked into
pathways involved in survival. In contrast, CXCR7, the other
receptor of CXCL12, is not expressed on the surface of CLL cells
although it is expressed on normal B cells [6]. Thus, while there is
overlap insignalingpathwaysactivated byCXCL12 inCLLcellsand
normal B cells, the differences in migration and CXCR7 expression,
and the potential bias towards survival in CLL cells, suggest
significant differences in the role that the CXCL12/CXCR4 axis
plays in the context of the normal and pathological cells.
Phosphoproteomics analysis of CXCL12-stimulated CLL cells
was performed in an effort to determine potential downstream
signaling targets that could contribute to the survival and
malignancy of CLL cells. As these are precious non-renewable
primary patient cells, the intent of our phosphoproteomics
approach was to generate hypotheses rather than an exhaustive
analysis of the CLL phosphoproteome. Therefore, while it would
be ideal to use a number of phospho-enrichment strategies in
addition to IMAC (e.g. TiO2) and to employ additional liquid
chromatography separation steps besides C18 (e.g. hydrophilic
interaction liquid chromatography (HILIC)) to expand the
number of phosphoproteins identified, we focused our efforts on
well established methods [10,31]. Along these lines, the use of
quantitative phosphoproteomics strategies is limited since these
cells do not replicate and cannot be cultured long term. Thus,
stable isotope labeling of amino acids in cell culture (SILAC) is not
possible [32]. Post-digest labeling with iTRAQ or ICAT isotopic
labels [32] is also difficult due to limited sample availability,
limitations in instrumentation (one-third rule with the LTQ
spectrometer restricting detection of the labels in the low
molecular weight range) [33], and the labile nature of phosphates
and labels which causes reduced fragmentation and detection in
MS/MS spectra [34]. While understanding its limitations, spectral
counting was employed as a semi-quantitative assessment of the
CXCL12-stimulation responses [35] and several candidates were
followed up by western blot validation. In addition to the above
examples with PDCD4 and HSP27, which showed that the
spectral counting provides a relatively good approximation of
stimulation response, spectral counts reflecting fairly even levels of
phosphorylated p21-activated kinase (PAK2), another target of the
PI3K pathway, was also confirmed by western blot in all six
patient cells probed for phospho-PAK2 (Ser141) (Figure S3).
Through this phosphoproteomics approach, we were able to
confidently identify close to 700 phosphoproteins in the CLL
samples, including numerous proteins previously implicated in
CLL disease. Additionally, we identified many proteins that
appear to exhibit changes in phosphorylation levels in response to
CXCL12. This data led to the identification and validation of
several previously unknown phosphorylation targets of CXCL12
signaling. Typical approaches (e.g. western blot) for investigating
signaling in response to stimuli require a priori knowledge of
specific targets and the availability of phospho-specific antibodies,
which limits the ability to globally assess cellular signaling events.
Furthermore, validation studies of CLL cells are difficult since
their viability in culture is limited. They are also difficult to
manipulate through transfection and transduction since they do
not divide in culture or infect well (e.g. they require high MOI
and/or pre-activation of cells with CD40L and IL-4 [36] which
could complicate interpretation of signaling analysis). Therefore,
this mass-spectrometry-based approach seemed the most effective
method for gaining new insight into the function of CXCL12 on
CLL cell survival and possibly disease aggressiveness. Although
Figure 6. Phosphorylation of HSP27 in Subset of CLL Patients.
A) Bar graph depicting the spectral counts of HSP27 phosphopeptides
(Ser82) observed in the LC-MS/MS analysis after CXCL12 stimulation. B)
Western blot detecting phosphorylation of HSP27 and the upstream
p38-MAPK, and total HSP27 over time course of 0 to 60 min CXCL12
stimulation (30 nM) from CLL A patient cells and 2 other representative
CLL patients’ cells. b-actin was run as a loading control. C) Signaling
diagram of HSP27, which can protect from apoptosis, and its upstream
regulation by p38-MAPK and MAPKAPK2.
doi:10.1371/journal.pone.0011716.g006
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patients may help to distinguish variations between patients, and
with disease stratification and the identification of judicious
therapeutic targets.
To our knowledge, this is the first report demonstrating that
PDCD4 is a phosphorylation target downstream of CXCL12
signaling in CLL or other cell types. This finding is exciting due to
the established role of PDCD4 as a tumor suppressor and as a
substrate of Akt [23,25]. Although little is known regarding the
function of two of the phosphorylation sites of PDCD4 (Ser94 and
Ser76) identified from the LC-MS/MS analysis, phosphorylation
at Ser457 near the C-terminus of the protein is a well-established
site with known functional implications. Phosphorylation at
Ser457 by Akt has been shown to result in nuclear translocation
of PDCD4 and a decrease in its ability to inhibit AP-1-mediated
transcription and eIF4A-mediated translation [24,26]; although
Ser67 phosphorylation was not directly identified in our LC-MS/
MS analysis, it is likely that this sight is also phosphorylated in
response to CXCL12 stimulation since PDCD4 degradation was
observed following stimulation [23,25]. In combination, these
effects may reduce the growth regulating/tumor-suppressor
capacity of PDCD4, thereby contributing to CLL cell survival
and the malignancy phenotype. Validation of PDCD4 phosphor-
ylation also led to the identification of p70S6K phosphorylation
and activation downstream of CXCL12 signaling in CLL cells.
Based on the phosphoproteomics analysis, HSP27 appeared to
be another promising phosphorylation target of CXCL12-
signaling. HSP27 and several other HSPs have received attention
in the context of cancer due to their cytoprotective/anti-apoptotic
functions. Specifically, HSP27 indirectly inhibits cytochrome c
release and caspase activation and it sequesters cytosolic
cytochrome c. It also promotes degradation of the inhibitor of
NF-kB (IkB) and p27kip, and interacts with and supports the
activity of Akt under stressful conditions, all leading to protection
from apoptosis [29,37]. We identified the presence of phosphor-
ylated and total HSP27 protein and its upstream activator p38-
MAPK in a subset (,25%) of cell samples from different CLL
patients. Of note, the observed variability in signaling between
different CLL patient cells highlights the underlying heterogeneity
of the disease. Furthermore, it serves as a reminder of how
different parameters including patient differences (age and
gender), variations in clinical course such as aggressiveness, stage
and prognosis, and different treatments (e.g. chemotherapy, gene
therapy, etc) may alter how the cells respond to different stimuli.
Such variability is not unprecedented as Messmer et al (submitted
manuscript) have demonstrated differences in CXCL12-mediated
MEK and ERK activation in different ZAP-70 subgroups of CLL,
and Montresor et al demonstrated differences in CXCL12-
mediated lymphocyte function-associated antigen-1 (LFA-1) acti-
vation in normal B cells compared to CLL B cells and amongst the
cells of different CLL patients [38]. Thus, it is reasonable to expect
that different patients will exhibit different responses to stimuli,
whether it is a survival stimulus from the microenvironment or a
therapeutic agent used to treat the disease.
These results showing patient variability in HSP27 expression
emphasize the strength of utilizing primary cells for understanding
Figure 7. Summary of CXCL12-mediated Signaling in CLL. Signaling diagram depicting pathways activated downstream of CXLC12. Through
direct or indirect mechanisms, arrows indicate factors that are activated, red lines ending with a bar indicate factors that are inhibited by the
upstream factor, and lines (no arrowhead) indicate interactions. Proteins in hexagons were identified and validated herein or were previously known
targets also detected in the LC-MS/MS. Proteins in rectangles are known key signaling molecules of these pathways that were not detected in this LC-
MS/MS data set. Proteins in ovals with dashed lines are likely intermediates/targets of the pathways based on previous studies. Proteins in oval shape
were also identified by LC-MS/MS but have yet to be validated. Much of our focus has been on the PI3K/Akt and Raf/MEK/ERK pathways due to
known implications in CLL cell survival and resistance to apoptosis. Furthermore, the potential involvement of the p38-MAPK pathway in some CLL
patients with activation of HSP27 and LSP1 is outlined.
doi:10.1371/journal.pone.0011716.g007
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homogenous, but can be less insightful and sometimes misleading.
While there was considerable overlap in the phosphoproteins
identified from LC-MS/MS analysis between different patients
(CLL A – E), more comprehensive MS analysis of multiple
patients may help to distinguish variations in signaling responses
between patients. Along these lines, since HSP27 is often induced
following stressful cellular events such as treatment with
chemotherapeutics, its induction in certain patients could reflect
a response to treatment. For example, lymphoma cells which did
not express Hsp27 were sensitive to apoptosis while those
expressing Hsp27 were resistant to apoptosis induced by
Bortezomib (PS-341), a proteasome inhibitor [39]. Silencing of
Hsp27 in the resistant lymphoma cells then rendered them
susceptible to Bortezomib-induced death, demonstrating its link in
resistance to this chemotherapeutic treatment [39]. Thus, a larger
patient sample size may reveal if expression of HSP27 is induced
by certain chemotherapeutics or in particular subsets of patients
and whether there is any correlation to refractory disease, as
resistance to chemotherapy is one of the major hurdles in treating
CLL [2].
Herein we present follow-up data to PDCD4 and HSP27,
although there are numerous other candidate phosphoprotein
targets of CXCL12 signaling in CLL cells that have been proposed
(Table 2). A summary of our findings from phosphoproteomics
analysis combined with some previously established pathways of
CXCL12 signaling in CLL are summarized in a signaling diagram
(Figure 7). Overall, our data suggests that CXCL12 may
preferentially activate survival signaling pathways rather than
those involved in cell migration in CLL cells, although some of the
pathway components (Gi, Erk, Akt) are common nodes. We have
demonstrated that the use of phosphoproteomics is a feasible and
informative means of evaluating signaling responses to CXCL12
in CLL, which could be employed for investigating a variety of
other stimuli in these or other primary cells. Through phospho-
proteomics detection and western blot validation, PDCD4 was
found to be a common phosphorylation target of CXCL12-
signaling in CLL while HSP27 was present in only a subset of CLL
patients. Although our focus was on CXCL12 as a survival factor,
it is likely that other growth and survival stimuli may synergistically
activate these pathways and downstream targets. Therefore,
PDCD4 and HSP27, which have previous implications in
regulation of apoptosis and carcinogenesis, may represent
potential therapeutic targets for treatment of CLL. In fact, small
molecule stabilizers of PDCD4, that enhance its function as a
tumor suppressor by inhibiting its degradation, are currently being
developed due to its potential as a therapeutic target for numerous
cancers. Such agents could prove to be useful agents in
combination with other therapeutic modalities for the treatment
of CLL [40].
Supporting Information
Table S1 Table of all phosphoproteins and corresponding
phosphopeptides identified by LC-MS/MS analysis on IMAC
enriched CLL samples.
Found at: doi:10.1371/journal.pone.0011716.s001 (0.18 MB
XLS)
Figure S1 Mass spectra of PDCD4 phosphopeptides. Mass
spectra from the 3 phosphopeptides from PDCD4 that were
identified in the LC-MS/MS analysis. The top spectrum (A)
represents the phosphopeptide with Ser457, which is the
phosphosite detected by the antibody used in follow-up western
blot analysis. B) Spectrum for Ser94 phosphorylation site. C)
Spectrum for Ser76 phosphorylation site.
Found at: doi:10.1371/journal.pone.0011716.s002 (0.10 MB
DOC)
Figure S2 Mass spectrum of HSP27 phosphopeptide. Mass
spectrum from the HSP27 phosphopeptide (Ser 82) that was
identified in the LC-MS/MS analysis.
Found at: doi:10.1371/journal.pone.0011716.s003 (0.04 MB
DOC)
Figure S3 Phosphorylation of PAK2 is present but not induced
by CXCL12 in CLL cells. A) Mass spectrum of the phosphopep-
tide K.YLSpFTPPEK.D (Ser141) of PAK2, which was present in
all proteomics runs but had fairly even spectral counts (1–3
spectra) in each CXCL12 stimulation time point). B) Represen-
tative western blot of PAK2 phosphorylation (Ser141) over 60 min
time course of 30 nM CXCL12 stimulation in 3 different CLL
patient’s cells reflects no changes in phospho-PAK2 upon
stimulation, although total phospho-PAK2 levels were variable
between different patients’ cells. b-actin served as a loading
control.
Found at: doi:10.1371/journal.pone.0011716.s004 (0.08 MB
DOC)
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